Hepatitis B – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Hepatitis B – Pipeline Review, H1 2020’, provides an overview of the Hepatitis B pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatitis B

– The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects

– The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatitis B

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatitis B

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abhelix LLC

Ai-biopharma SAS

AiCuris GmbH & Co KG

AIMM Therapeutics BV

Akshaya Bio Inc

Aligos Therapeutics Inc

AlphaMab Co Ltd

Alphamab Oncology

Altimmune Inc

Antios Therapeutics Inc

Arbutus Biopharma Corp

Arcturus Therapeutics Ltd

Ark Biosciences Inc

Ascentage Pharma Group International

Ascletis Pharma Inc

Assembly Biosciences Inc

Atea Pharmaceuticals Inc

Aucta Pharmaceuticals LLC

Avalia Immunotherapies Ltd

Beijing Advaccine Biotechnology Company Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Beijing Minhai Biotechnology Co Ltd

Benitec Biopharma Ltd

Biological E Ltd

Biomics Biopharma Ltd

BioNet- Asia Co Ltd

Biotron Ltd

Bolder Biotechnology Inc

Bonac Corp

Brandenburg Antiinfektiva GmbH

Brickell Biotech Inc

BrightGene Bio-Medical Technology Co Ltd

Bukwang Pharm Co Ltd

Cadila Healthcare Ltd

CaroGen Corp

Casterbridge Pharmaceuticals Inc

Chengdu Hyperway Pharmaceuticals

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Chong Kun Dang Pharmaceutical Corp

Chongqing Zhifei Biological Products Co Ltd

Cinkate Corp

CN Bio Innovations Ltd

Cocrystal Pharma Inc

Collaborations Pharmaceuticals Inc

CyTuVax BV

Decoy Biosystems Inc

DelSiTech Ltd

Dicerna Pharmaceuticals Inc

Dong-A Socio Holdings Co Ltd

Dynavax Technologies Corp

Elixiron Immunotherapeutics Inc

Enanta Pharmaceuticals Inc

Enochian Biosciences Inc

Enyo Pharma SA

Etna Biotech Srl

Excision BioTherapeutics Inc

F. Hoffmann-La Roche Ltd

FortuneRock (China) Ltd

Fujian Cosunter Pharmaceutical Co Ltd

GC Pharma

GemVax & KAEL Co Ltd

GeneCure LLC

GeneScience Pharmaceuticals Co Ltd

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

Guangxi Hebabiz Pharmaceutical Co Ltd

Guangzhou Yipinhong Pharmaceutical Co Ltd

HEC Pharm Co Ltd

Hepion Pharmaceuticals Inc

Huahui Anjian (Beijing) Biotechnology Co Ltd

Humabs BioMed SA

Huons Co Ltd

ImmuneMed Inc

Immunocore Ltd

Immunotope Inc

ImQuest Life Sciences Inc

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

ISR Immune System Regulation Holding AB

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Johnson & Johnson

Kainos Medicine Inc

KinoPharma Inc

LG Chem Ltd

Ligand Pharmaceuticals Inc

Lion TCR Pte Ltd

Microbiotix Inc

MYR GmbH

Novo Medi Sciences Pvt Ltd

Nucorion Pharmaceuticals Inc

Oncolys BioPharma Inc

Palisades Therapeutics

PharmaEssentia Corp

Precision Biosciences Inc

Profarma

Profectus BioSciences Inc

Qilu Pharmaceutical Co Ltd

Regeneron Pharmaceuticals Inc

Regulus Therapeutics Inc

Replicor Inc

Rodos BioTarget GmbH

Romark Laboratories LC

Samjin Pharm Co Ltd

Sclnow Biotechnology Co Ltd

Scynexis Inc

SFA Therapeutics LLC

Shanghai Henlius Biotech Inc

Shanghai Zhimeng Biopharma Inc

Shantha Biotechnics Pvt Ltd

Shenzhen BinDeBio Ltd

Sinovac Biotech Ltd

SL VaxiGen Inc

Staidson BioPharma Inc

Suzhou Ribo Life Sciences Co Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

TCM Biotech International Corp

TeneoBio Inc

Tetranov International Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Transgene SA

UBI Pharma Inc

Vaccitech Ltd

Vaxart Inc

Vaxine Pty Ltd

VBI Vaccines Inc

VenatoRx Pharmaceuticals Inc

Vir Biotechnology Inc

Viravaxx AG

Viriom Inc

Virion Therapeutics LLC

Virocovax

ViroStatics SRL

VLP Biotech Inc

Xi’an Xintong Pharmaceutical Research Co Ltd

Yisheng Biopharma Co Ltd

Table of Contents

Table of Contents

Introduction

Hepatitis B - Overview

Hepatitis B - Therapeutics Development

Hepatitis B - Therapeutics Assessment

Hepatitis B - Companies Involved in Therapeutics Development

Hepatitis B - Drug Profiles

Hepatitis B - Dormant Projects

Hepatitis B - Discontinued Products

Hepatitis B - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hepatitis B, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Hepatitis B – Pipeline by Abhelix LLC, H1 2020

Hepatitis B – Pipeline by Ai-biopharma SAS, H1 2020

Hepatitis B – Pipeline by AiCuris GmbH & Co KG, H1 2020

Hepatitis B – Pipeline by AIMM Therapeutics BV, H1 2020

Hepatitis B – Pipeline by Akshaya Bio Inc, H1 2020

Hepatitis B – Pipeline by Aligos Therapeutics Inc, H1 2020

Hepatitis B – Pipeline by AlphaMab Co Ltd, H1 2020

Hepatitis B – Pipeline by Alphamab Oncology, H1 2020

Hepatitis B – Dormant Projects, H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..1), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..2), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..3), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..4), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..5), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..6), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..7), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..8), H1 2020

Hepatitis B – Dormant Projects, H1 2020 (Contd..9), H1 2020

Hepatitis B – Discontinued Products, H1 2020

Hepatitis B – Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Hepatitis B, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports